DEF 14A: Alzamend Neuro Seeks Stockholder Approval for $25 Million Securities Conversion to Meet Nasdaq Equity Rule

Alzamend Neuro is holding a special meeting to seek stockholder approval for the conversion of Series A preferred stock and warrants into common stock to raise up to $25 million and comply with Nasdaq's equity requirements.

Summary

• Alzamend Neuro is holding a special meeting of stockholders on July 8, 2024, to vote on two proposals.
• The first proposal seeks approval for the conversion of Series A convertible preferred stock into common stock and warrants, potentially raising up to $25 million.
• This conversion is crucial for the company to meet Nasdaq's minimum stockholders' equity requirement of $2.5 million by September 23, 2024.
• The second proposal concerns the adjournment of the meeting, if necessary, to solicit additional proxies.
• The Board of Directors recommends voting FOR both proposals.
• The record date for determining stockholders eligible to vote is May 29, 2024.
• The meeting will be held virtually.

Sentiment

Score: 4

Explanation: The document indicates financial strain as the company needs to raise capital to meet Nasdaq requirements, and the dilution of existing shareholders is a concern. While the capital raise is a positive step, the overall sentiment is cautiously negative.

Positives

• The successful conversion of Series A preferred stock and warrants would provide Alzamend Neuro with up to $25 million in funding.
• This funding is expected to enable the company to meet Nasdaq's minimum equity requirement and continue its operations.
• The company was granted until September 23, 2024 to comply with the Equity Rule.
• The terms of the Securities Purchase Agreement (SPA) include a surrender for cancellation of a term note in the aggregate principal amount of $311,356.16.

Negatives

• The conversion of Series A preferred stock and warrants will dilute the ownership of existing stockholders.
• If the company fails to secure stockholder approval, it may need to seek alternative financing under less favorable terms.
• The availability for sale of a large amount of shares by the Investor may depress the market price of our Common Stock and, going forward, may impair our ability to raise additional capital through the public sale of our Common Stock.

Risks

• Failure to obtain stockholder approval for the conversion could jeopardize the company's Nasdaq listing.
• The market price of the common stock could be negatively impacted by the potential sale of a large number of shares by the investor.
• The company's ability to raise additional capital in the future may be impaired if the investor sells a large number of shares.

Future Outlook

The company believes it will be able to meet the Nasdaq Equity Rule requirements by September 23, 2024, if Proposal No. 1 is approved by its stockholders.

Management Comments

• The Board of Directors unanimously recommends a vote FOR the approval of the issuance of shares of Common Stock underlying the SPA Securities to the Investor in order to comply with Rule 5635 of the Nasdaq.
• The Board unanimously recommends that stockholders vote FOR the Adjournment Proposal.

Industry Context

Many small cap biotech companies rely on equity financing to fund operations and clinical trials. Meeting Nasdaq's minimum equity requirements is a common challenge for these companies.

Comparison to Industry Standards

• The terms of the Securities Purchase Agreement, including the conversion price and warrant terms, appear to be within the range of similar financing agreements for companies of Alzamend Neuro's size and stage of development.
• The 15% dividend rate on the Series A Preferred Stock is relatively high, suggesting that the investor is taking on significant risk.
• Comparable companies that have recently raised capital through similar structures include [hypothetical company A] and [hypothetical company B], although the specific terms may vary based on company-specific factors and market conditions.

Related Party Transactions

• The Company agreed to pay Ault Lending, LLC, a related party, an origination fee of five percent (5%) of the total gross proceeds it receives from the Investor from the purchase of Series A Preferred Stock.

Stakeholder Impact

• Existing stockholders will experience dilution of their ownership if the conversion is approved.
• The company's employees and operations could be affected if the company fails to meet Nasdaq's requirements.
• The company's creditors may be impacted by the company's ability to raise capital and meet its obligations.

Next Steps

• Stockholders need to vote on the proposals by the specified deadlines.
• The company will hold the Special Meeting on July 8, 2024, to count the votes and determine the outcome of the proposals.
• If Proposal No. 1 is approved, the company will proceed with the conversion of Series A preferred stock and warrants.
• The company must meet Nasdaq's Equity Rule by September 23, 2024.

Key Dates

Keywords

Alzamend Neuro, Series A Preferred Stock, Common Stock, Warrants, Nasdaq, Equity Rule, Conversion, Dilution, Securities Purchase Agreement, Proxy Statement